MRPL3 Prognostic Biomarker Model for Lung Adenocarcinoma

A 2026 study by Lan Yin presents a prognostic gene signature model for lung adenocarcinoma (LUAD) based on lactylation and disulfidptosis. The model was constructed using gene expression profiles from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) cohorts. MRPL3 was identified as a key biomarker and validated through in vitro and in vivo experiments.

Use Cases

• Constructing prognostic models for lung adenocarcinoma based on lactylation and disulfidptosis gene signatures.
• Identifying potential therapeutic targets like MRPL3 based on correlation with poor prognosis and tumor stage.
• Analyzing the relationship between gene expression and immunosuppressive tumor microenvironment features.
• Validating biomarker roles through experimental knockdown studies on cell proliferation and migration.
• Investigating links between glycolytic metabolism, lactylation levels, and disulfidptosis evasion mechanisms.

Strengths

• The model was validated across multiple cohorts including a testing set, validation set, and external validation cohorts.
• Experimental validation includes both in vitro (cell proliferation, migration, lactylation levels) and in vivo (xenograft tumor growth) results.
• The dataset is openly licensed under CC-BY-4.0.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is a 12.0 KB DOCX file, suggesting it likely contains summary results or a manuscript rather than raw expression data.

Provenance

Source

Gene expression profiles from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) cohorts.

Collection Method

Differential expression analysis, correlation analysis, univariate survival analysis, LASSO regression, and experimental validation.

Freshness

Last updated 2026-05-19 05:38:47; freshness should be verified.